Trial reportArchives of neurology2012
Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens.
Trial report in Archives of neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00378326 (Immunotherapy of the Paraneoplastic Syndromes), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunotherapy of the Paraneoplastic Syndromes
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Paraneoplastic Intracellular Neuropathies: A Narrative Review.Neurology and therapy · 2026Review
- Toward curing neurological autoimmune disorders: Biomarkers, immunological mechanisms, and therapeutic targets.Neuron · 2025Review
- Ovarian mass Presenting as Paraneoplastic cerebellar degeneration with peripheral neuropathy and anti-Yo antibody.BMJ case reports · 2024Article
- Clinical scales in autoimmune encephalitis-A retrospective monocentric cohort study.Annals of clinical and translational neurology · 2023Article
- Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes.Antibodies (Basel, Switzerland) · 2023Review
- Paraneoplastic neurological syndromes: clinical presentations and management.Therapeutic advances in neurological disorders · 2021Review
- Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.Neuropathology and applied neurobiology · 2019Article
- Treating Immune-Related Epilepsy.Current neurology and neuroscience reports · 2018Review
- Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis.Ecancermedicalscience · 2018Article
- Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Frontiers in immunology · 2018Review
- Treatment of Cerebellar Ataxia in the Context of Systemic Diseases.Current treatment options in neurology · 2017Review
- Article
- Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Antibodies as Mediators of Brain Pathology.Trends in immunology · 2015Review
- A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease.Annals of neurology · 2015Article
- Neuroinflammation: Ways in Which the Immune System Affects the Brain.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome.Clinical and experimental immunology · 2014Article
- 7th International Immunoglobulin Conference: Interlaken Leadership Awards.Clinical and experimental immunology · 2014Article
- T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation.European journal of immunology · 2014Article
- Paraneoplastic neurological syndromes: general treatment overview.Current treatment options in neurology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND Tumor treatment is the mainstay of therapy for paraneoplastic neurologic disorders (PNDs), but it is only effective in some cases and other treatment options are limited. OBJECTIVE To evaluate the short-term use of a combination of prednisone and tacrolimus for acute neurologic worsening in PND in which intracellular antigens are targeted. DESIGN Retrospective single-center case series of patients with PND treated with tacrolimus. SETTING The Rockefeller University Hospital, a research hospital in New York, New York. PATIENTS Twenty-six patients with PND with high titer (≥1:1000) anti-HuD, anti-Yo, or anti-CRMP5 autoantibodies were enrolled. Patients were referred from Memorial Sloan Kettering Cancer Center or self-referred. Two patients discontinued intervention owing to adverse events. INTERVENTIONS Patients were treated with tacrolimus, 0.15-0.30 mg/kg per day, in 2 divided oral doses with 60 mg per day of oral prednisone, tapered off during 1 to 4 weeks. MAIN OUTCOME MEASURES The primary outcome measure was median survival. Neurologic examinations before and after treatment as well as adverse events are described. RESULTS Median survival time was 52 months from time of diagnosis. Some patients experienced neurologic improvement that was functionally meaningful. The incidence of adverse events was similar to that generally reported with tacrolimus. CONCLUSIONS A short course of prednisone and tacrolimus to target central nervous system T cells in patients with PND with acute neurologic decline in which intracellular antigens are targeted was well tolerated and warrants further study. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00378326.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.